User Rating 0.0 ★★★★★

Total Usage 0 times

Category Medicine & Tests

Mass Length (L) cm Largest craniocaudal diameter

Mass Height (H) cm Largest anteroposterior diameter

Mass Width (W) cm Largest transverse diameter

Head Circumference (HC) cm Fetal HC at standard axial plane

Gestational Age weeks Optional. For clinical context (16–40 wk).

Enter measurements and click Calculate

Is this tool helpful?

Your feedback helps us improve.

★ ★ ★ ★ ★

About

Congenital Pulmonary Airway Malformation (CPAM), formerly classified as Congenital Cystic Adenomatoid Malformation (CCAM), presents a measurable risk of fetal hydrops when the lesion volume grows disproportionately to head size. The CPAM Volume Ratio (CVR) quantifies this relationship by dividing the estimated mass volume by the head circumference. Crombleholme et al. (2002) established a CVR threshold of 1.6: fetuses with CVR ≥ 1.6 carry approximately 80% risk of developing hydrops fetalis, while those below this threshold carry roughly 3% risk. This calculator uses the prolate ellipsoid approximation (V = 0.52 × L × H × W) standard in obstetric imaging. Note: the formula assumes an ellipsoid geometry and may underestimate irregular or multilobar lesions. Serial measurements at 1 - 2 week intervals between 20 - 32 weeks gestation are recommended, as CPAM growth typically peaks near 25 - 28 weeks.

Formulas

The CPAM mass volume is estimated using the prolate ellipsoid formula, standard in obstetric sonography for solid or mixed lesions:

V = 0.52 × L × H × W

Where V is the estimated volume in cm³, L is the largest longitudinal diameter in cm, H is the largest anteroposterior (height) diameter in cm, and W is the largest transverse (width) diameter in cm. The constant 0.52 is derived from π6 ≈ 0.5236, rounded for clinical use.

The CPAM Volume Ratio is then computed as:

CVR = VHC

Where HC is the fetal head circumference in cm. The resulting CVR is dimensionless (cm³ ÷ cm = cm², but clinically treated as a ratio index). A CVR ≥ 1.6 indicates high risk for hydrops fetalis as established by Crombleholme (2002). Fetuses with dominant cysts > 5 cm may develop hydrops regardless of CVR due to mediastinal shift, and should be evaluated independently.

Reference Data

CVR Range	Risk Category	Hydrops Risk	Recommended Action
< 0.56	Very Low	< 1%	Routine follow-up every 2-4 weeks
0.56 - 0.99	Low	≈ 2 - 3%	Serial ultrasound every 1-2 weeks
1.0 - 1.59	Moderate	≈ 3 - 10%	Weekly ultrasound, MFM consultation
1.6 - 1.99	High	≈ 50 - 80%	Betamethasone consideration, fetal center referral
≥ 2.0	Very High	> 80%	Urgent intervention planning (thoracoamniotic shunt, EXIT)
CPAM Classification (Stocker)
Type 0	Acinar dysplasia. Incompatible with life. Diffuse involvement of both lungs.
Type I	Large cysts (> 2 cm). Most common (60 - 70%). Best prognosis.
Type II	Medium cysts (0.5 - 2 cm). 15 - 20% of cases. May associate with other anomalies.
Type III	Microcystic/solid (< 0.5 cm). 5 - 10%. Higher hydrops risk due to solid bulk.
Type IV	Distal acinar origin. Large thin-walled cysts. Distinguished from Type I histologically.
Gestational Age Landmarks
18 - 20 wk	Anatomy scan. CPAM first detectable. Baseline CVR measurement.
25 - 28 wk	Peak CPAM growth. Highest hydrops risk window. Most critical monitoring period.
28 - 32 wk	Plateau or regression common. CVR often decreases. Betamethasone window if CVR high.
> 32 wk	Most lesions stabilize. Delivery planning. Postnatal CT at 3-6 months.
Key Clinical Constants
Ellipsoid Constant	0.52	Approximation of π/6 ≈ 0.5236
Hydrops Threshold CVR	1.6	Crombleholme et al. (2002), validated by Cass et al. (2011)
Mean HC at 20 wk	17.5 cm	Hadlock reference tables
Mean HC at 28 wk	26.5 cm	Hadlock reference tables
Mean HC at 32 wk	29.5 cm	Hadlock reference tables

Frequently Asked Questions

Crombleholme et al. analyzed 67 fetuses with CPAM and found that a CVR of 1.6 optimally separated those who developed hydrops (~80% above threshold) from those who did not (~3% below). This threshold was subsequently validated by Cass et al. (2011) in a larger cohort. Some centers use 1.6 as a "trigger" for maternal betamethasone administration or fetal intervention referral.

Yes. Approximately 3% of fetuses with CVR below 1.6 still develop hydrops. This occurs more often when a dominant macrocyst larger than 5 cm causes mediastinal shift independent of total lesion volume. The CVR captures bulk effect but not focal compression. Serial monitoring remains essential even at low CVR values.

The prolate ellipsoid formula (V = 0.52 × L × H × W) overestimates true volume by approximately 10-30% compared to MRI segmentation, because CPAM lesions are rarely perfect ellipsoids. However, since the original Crombleholme thresholds were derived using this same formula, consistency matters more than absolute accuracy. Using MRI volumes with ultrasound-derived thresholds would introduce systematic bias.

CVR is most clinically relevant between 20 and 32 weeks gestation. CPAM growth typically peaks at 25-28 weeks. A rising CVR during this window is more concerning than a static elevated value. After 28-30 weeks, many lesions plateau or regress. A CVR measured before 20 weeks may not reflect the eventual peak volume.

Multiple case series report that maternal betamethasone (12 mg IM × 2 doses, 24 hours apart) can reduce CVR by 20-50% in microcystic (Type III) lesions within 1-2 weeks. Macrocystic lesions (Type I) respond less reliably. The mechanism is thought to involve reduced cellular proliferation and fluid secretion within the malformation. Post-steroid CVR should be monitored separately from pre-treatment values.

Measure the three largest orthogonal diameters of the CPAM mass on ultrasound: length (longitudinal/craniocaudal), height (anteroposterior), and width (transverse). Each measurement should be taken at the maximum visible extent of the lesion. For lesions with a dominant macrocyst, measure the solid and cystic components together as one mass. Head circumference should be measured in the standard axial plane at the level of the thalami and cavum septi pellucidi using the ellipse tool.

Both are congenital lung lesions, but pulmonary sequestrations receive systemic arterial supply (visible on Doppler) and lack bronchial communication. Hybrid lesions (CPAM with sequestration features) occur in roughly 25% of cases. The CVR formula applies equally to any solid/cystic chest mass, regardless of histological subtype. The clinical threshold of 1.6 was validated across mixed lesion types.